BREAKING THERAPEUTIC INERTIA WITH ALIROCUMAB IN AN 80-YEAR-OLD PATIENT WITH SEVERE HYPERCHOLESTEROLEMIA: A CASE REPORT

Angela Dardano*, Giuseppe Daniele, Giuseppe Penno, Roberto Miccoli and Stefano Del Prato

Section of Diabetes, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Background: Therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely manner as per evidence-based clinical guidelines, is an important barrier limiting optimal care in the elderly. Therefore, overcoming therapeutic inertia is the core challenge when dealing with geriatric patients.

Case Description: The patient was an 80-year-old man that attended our Outpatient Lipid Clinic (Pisa University Hospital) because of persistent high LDL cholesterol (LDLc) levels in a setting of a statin contraindication. He underwent five percutaneous coronary angioplasties with drug-eluting stents. In 2014, upon starting treatment with rosuvastatin for LDLc level of 7.59 mmol/L, the patient was admitted to the Emergency Room for a presumptive diagnosis of rhabdomyolysis (creatine kinase 6685 U/L) secondary to statin. Patient developed acute kidney injury treated with dialysis. After resolution, he was discharged with ezetimibe (10 mg daily). This treatment however failed to effectively reduce LDLc levels that ranged between 5.9 and 6.6 mmol/L for the ensuing 4-years. In 2018, at the time of our evaluation, in consideration of the age, we performed a comprehensive geriatric assessment that showed good functional and mental status supporting a reliable treatment with a proprotein convertase subtilisin–kexin type 9 inhibitor. Therefore, alirocumab was prescribed as add-on to ezetimibe. At 24-month follow-up, the geriatric assessment showed no significant changes, and alirocumab was well-tolerated. LDLc was 82% lower as compared to baseline values (from 6.6 to 1.2 mmol/L).

Conclusions: This report describes a case of therapeutic inertia despite a very high-risk profile. It is also instrumental in highlighting that appropriate intensification of therapy in an elderly patient at high cardiovascular risk, by means of a patient-centered approach, may allow reaching therapeutic targets and overcoming the condition of therapeutic inertia.

Keywords: LDL cholesterol, PCSK9 inhibitors, alirocumab, elderly, case report, therapeutic inertia, hypercholesterolemia
INTRODUCTION

The original concept of clinical inertia was highlighted by Phillips et al. (1) in 2001 who defined it as the failure to initiate or intensify therapy in a timely manner as per evidence-based clinical guidelines, thus emerging as an important barrier limiting optimal care in patients with chronic diseases such as type 2 diabetes mellitus (2), hypertension (3), dyslipidemia (4), coronary artery disease (5), and heart failure (6). Most of the literature on clinical inertia relate to failure to introduce appropriate therapies when treatment goals are not being met. However, in view of the wider application of the term, recent positions suggest that clinical inertia should be reserved for "lack of adherence to guideline recommendations when appropriate to do so," with therapeutic inertia being used for "failure to advance therapy or to de-intensify therapy when appropriate to do so" (7). For our purpose we have agreed to use the term therapeutic inertia. Here we report a case of therapeutic inertia concerning an 80-year-old patient with high cholesterol levels and coronary ischemic heart disease. The patient was not treated with statins because of a previous episode of rosuvastatin-related rhabdomyolysis and other lipid-lowering drugs (i.e., proprotein convertase subtilisin/kexin type 9 enzyme inhibitors, PCSK9 inhibitors) were not prescribed despite his very high-risk profile. Therefore, the therapeutic targets set by clinical guidelines were not achieved for a long time.

CASE PRESENTATION

In July 2018, an 80-year-old-man was referred to our Outpatient Lipid Clinic (Pisa University Hospital) for the management of hypercholesterolemia in a setting of a statin contraindication. The patient had a family history of premature coronary artery disease and hypercholesterolemia. He used to be a heavy cigarette smoker. His medical history included ischemic heart disease, systemic hypertension, hyperuricemia, impaired fasting plasma glucose, and chronic kidney disease (stage 3a). In 2008, at the age of 70 years, the patient presented to the Emergency Room with epigastric pain. The initial ECG showed ST segment elevation from V2 to V6, I and aVL, with ST depression in inferior leads. Impaired left ventricular systolic function (EF 35%) and 3-vessel coronary artery disease were detected by echocardiographic and angiographic examination, respectively. He was treated with percutaneous coronary angioplasty and drug-eluting stents. The patient’s cardiovascular history was silent until his first heart attack in 2008, when he started therapy with atorvastatin 80 mg once daily. He subsequently underwent multiple coronary revascularization procedures following the onset of inducible myocardial ischemia (from 2008 to 2013). In 2014, upon starting treatment with rosuvastatin 5 mg once daily for LDL cholesterol (LDLc) level of 7.59 mmol/L, the patient was admitted to the Emergency Room of a local hospital for generalized myalgia and muscle weakness impairing mobility. He also reported oliguria with dark urine ("tea-color") 2 days prior to hospital admission. Lab investigations revealed elevated creatine kinase (CK) levels, peaking at 6685 U/L (normal values < 190 U/L), creatinine 123.8 µmol/L (normal values 61.9–106.1 µmol/L) and potassium 5.3 mmol/L (normal values 3.5–5.1 mmol/L). A urine dipstick was positive for myoglobinuria. No specific etiology was identified to account for the rhabdomyolysis other than statin therapy. Muscle biopsy was not performed, and rosuvastatin was withdrawn. Intravenous fluid administration was provided, however acute kidney injury developed with elevated potassium values that could not be controlled with i.v., insulin/dextrose infusion. Therefore, the patient underwent four dialysis sessions via a temporary vascular catheter. CK levels progressively declined (184 U/L) and the renal function improved so that the patient became dialysis-independent although residual impaired kidney function persisted (creatinine 150.3 µmol/L, stage 3b). Clinically, the patient reported a significant improvement in muscle symptoms, and he was discharged after a cycle of physiotherapy with a prescription of ezetimibe (10 mg daily) and diet with reduced daily intake of saturated- and trans-fatty acids. This treatment however failed to effectively reduce LDLc levels that ranged between 5.9 and 6.6 mmol/L for the ensuing 4-years (Figure 1).

In 2018, at the time of our evaluation, the patient was still on ezetimibe and lipid levels were: total cholesterol 9.5 mmol/L; LDLc 6.6 mmol/L; HDLc 1.3 mmol/L; non-HDL cholesterol 8.1 mmol/L, and triglycerides 3.5 mmol/L. Unfortunately, lipoprotein (a) [Lp(a)] levels were not assessed in our patient, although, Lp(a) is associated with a poor long-term prognosis in the elderly with ischemic heart disease and with an increased risk of stroke (8, 9). The physical examination was normal, according to the age. His temperature was 36.7°C, the pulse rate was 88 beats/min with a blood pressure of 140/80 mmHg on amlodipine (10 mg daily). On auscultation, a grade 2/6 systolic murmur was heard near the base of the heart. In consideration of the age, we performed a multidimensional geriatric assessment and results of the different fields of interest are shown in Table 1. The geriatric assessment showed good functional and mental status supporting the treatment intensification. Among the various drugs available, we excluded bile acid sequestrants, although, useful in the treatment of dyslipidemia (10) because of possible adverse effects, especially gastrointestinal, and interaction with other drugs that is a concern in the elderly frequently on polypharmacy. Therefore, we directed our choice toward the most modern approach available (i.e., proprotein convertase subtilisin-kexin type 9 inhibitors, PCSK9 inhibitors). Alirocumab 75 mg was prescribed subcutaneously once every 2 weeks as add-on to ezetimibe, without dose titration due to the patient’s reluctance. The patient underwent clinical evaluation and lab test follow-up at 3–6-month interval for 24 months. At this time point, the multidimensional geriatric assessment showed no significant changes in functional status, comorbidity, cognition, mental health and nutrition (Table 1) and no major geriatric syndromes (i.e., delirium, falls, incontinence, pressure ulcers, and functional decline) or disability have developed. Alirocumab was well-tolerated and based on electronic prescription report, with 100% treatment adherence. No adverse effects were reported and LDLc progressively decreased to >50% from baseline after 3 months of treatment, (2.6 mmol/L). A downward trend was confirmed at 6 and 12 months (2.3 and 2.4 mmol/L, respectively).
At 24 months, LDLc was 82% lower as compared to baseline values (from 6.6 to 1.2 mmol/L; Figure 1).

**METHODS**

Triglycerides, total and HDL cholesterol were determined in fasting blood samples by colorimetric enzymatic methods; non-HDL cholesterol was calculated by the following formula: total cholesterol – HDL cholesterol. LDL cholesterol was calculated by the Friedewald formula. Serum creatinine was measured by the modified Jaffe method, traceable to IDMS, and eGFR was calculated by the CKD Epidemiology Collaboration equation. All other parameters were measured by standard method.

**DISCUSSION**

To the best of our knowledge, this is a unique case report illustrating the possibility to overcome therapeutic inertia in an octogenarian with severe hypercholesterolemia and ischemic heart disease. Our patient had a very high cardiovascular risk, yet his LDLc levels were poorly controlled. This was
most likely the consequence of two aspects. The first refers
to the fact that the patient and the physician had been
reluctant to undertake potentially harmful treatment since severe
rhabdomyolysis with rosuvastatin had already occurred. The
second aspect could relate to the common feeling still existing
within the medical community that an adequate reduction in
LDLc levels may not be so relevant in the elderly and even more
so in the case of treatment of hypercholesterolemia with high intensity drugs.

“Therapeutic inertia” is multifactorial in nature, but old age is
a common contributing factor (11). However, although, older age
is certainly associated with increased morbidity and mortality,
chronological age it may be that relevant for many older people
as individuals age differently according to aging patterns also
known as “ageotypes” (13). Lack of trials exclusively designed
to include elderly people also contributes to therapeutic inertia
(14). Although, cholesterol lowering has been proven to be
essential for prevention and reduction of cardiovascular risk
in a wide range of individuals (15), the general perception is
that LDLc may not be so relevant in the elderly. As such,
older subjects are less likely to receive proper lipid lowering
treatment and much less likely to receive high-intensity lipid
lowering therapy. The use of statins in the elderly, up to 75
years of age, with the aim of reducing LDLc is suitable in
the case of patients on secondary prevention or at very high cardiovascular risk because of multiple concomitant risk factors,
whereas it would not be justified, with few exceptions, in the
case of patients >85 years of age (16). The clinical benefit of
LDLc reduction in elderly patients remains debated. However,
a recent meta-analysis has shown how in patients aged 75 years
and older, lipid lowering is as effective in reducing cardiovascular
events as it is in individuals younger than 75 years (17). These
results strengthen guideline recommendations for the use of
lipid-lowering therapies, including non-statin treatment, in older
patients as well (18).

Common concerns about aggressive treatment in the elderly
includes fears of adverse events, in particular muscle-related
effects of statins, ranging from pains to rhabdomyolysis (19)
as it was the case for our patient. As a result, treatment
was limited to ezetimibe allowing no more than 15–20%
reduction of LDLc levels. Nonetheless, treatment intensification
with a PCSK9-inhibitor was not considered even though these
agents have been available since 2015 for medical use and
reimbursed in Italy since 2017, where the rate of prescription
of PCSK9 inhibitors still appears below expectations (20). A
sub-analysis of the ODYSSEY OUTCOMES, although, this
trial was not specifically designed for the older population,
showed that alirocumab improved outcomes irrespective of
age (21) with no differences in adverse events between
alirocumab and placebo. Another factor that may support
therapeutic inertia with respect to PCSK9-inhibitors may be
represented by cost (22). Altogether, these factors account
for many patients to be excluded from effective treatment
only based on their age. Appropriate and careful distinction
between chronologic vs. physiologic age may provide sufficient
background for a more personalized therapeutic approach.
To this end, we applied a comprehensive geriatric evaluation
establishing that the patient’s physiological age and performance
did not contraindicate the use of a treatment capable of
achieving LDLc target levels. Therapeutic algorithms have been
recently developed that could improve prescription performance
if associated to a comprehensive geriatric evaluation (23). In
our case, simple and validated tools have contributed to
refine estimates of the risk and guide personalized treatment
thus maximizing the likelihood of a positive outcome. The
area of lipid-modulating agents is constantly evolving, and
new pharmacological molecules (e.g., inclisiran and bempedoic
acid) with novel mechanisms of action have recently been
approved (24). Having new opportunities in the treatment
of hypercholesterolemia could mark a major advance in the
care of patients with high and very high-risk cardiovascular
disease, and not only in statin-intolerant individuals. Adherence
and persistence to optimal therapy could be improved as
these new drugs are administered orally (bempedoic acid) or
subcutaneously every 6 months (inclisiran). Whether the recent
introduction of bempedoic acid or the introduction in the next
few months of inclisiran may help overcoming therapeutic inertia
in elderly people may be an option although it remains to be ascertain.

CONCLUSIONS

In conclusion, although, this case report is limited in its
applications to general patient care, it is instrumental
in highlighting that even in older patients with
dyslipidemia and high cardiovascular risk there is the need
to reach therapeutic goals to ensure effective reduction
of cardiovascular events. Misconceptions about age may
limit implementation of appropriate treatment. PCSK9
inhibitors can provide effective and safe reduction of LDL-
cholesterol in elderly patients with contraindication to the
use of statins. To plan treatment and facilitate decisions,
The clinician may rely on the first letters of the alphabet
“ABC” as an acronym for “Always the Best Care,” also for
the elderly.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this
article will be made available by the authors, without
undue reservation.

ETHICS STATEMENT

Written informed consent was obtained from the individual(s)
for the publication of any potentially identifiable images or data
included in this article.

AUTHOR CONTRIBUTIONS

AD, GD, GP, and RM have contributed to collection, analysis,
and interpretation of data. AD and GP was involved in
the management of the patient. AD performed the geriatric
evaluation and wrote the first and final version of the manuscript. SDP overviewed the discussion. All authors have critically revised the article, approved of the first and final version of the manuscript, and made substantial contribution to the conception of the work.

REFERENCES

1. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. (2001) 135:825–34. doi: 10.17323/0003-4819-135-9-200111060-00012
2. Khunti K, Gomes MB, Pocock S, Shrestakova MV, Pintat S, Fenici P, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. (2018) 20:427–37. doi: 10.1111/dom.13088
3. Josiah Willock R, Miller JB, Mohyi M, Abuzaanona A, Muminovic M, Levy PD. Therapeutic inertia and treatment intensification. Curr Hypertens Rep. (2018) 20:4. doi: 10.1007/s11906-018-0802-1
4. Zullig LL, Egbuonu-Davis L, Trasy A, Oshotse C, Goldstein KM, Bosworth HB. Countering clinical inertia in lipid management: expert workshop summary. Am Heart J. (2018) 206:24–29. doi: 10.1016/j.ahj.2018.09.003
5. Lázaro P, Murga N, Aguilar D, Hernández-Presa MA, INERTIA Study Investigators. Therapeutic inertia in the outpatient management of dyslipidemia in patients with ischemic heart disease. The inertia study. Rev Esp Cardiol. (2010) 63:1428–37. doi: 10.1016/S1885-5857(10)70277-2. [Epub ahead of print].
6. Verhestraeten C, Hegermont WA, Maris M. Clinical inertia in the treatment of heart failure: a major issue to tackle. Heart Fail Rev. (2020). doi: 10.1007/s10741-020-09979-z
7. Khunti K, Davies MJ. Clinical inertia—Time to reappraise the terminology? Prim Care Diabetes. (2017) 11:105–6. doi: 10.1016/j.pcd.2017.01.007
8. Sang T, Cheng N, Dang A, Lv N, Zhang W, Li Y, et al. Lipoprotein (a) is associated with poor long-term prognosis in patients aged 80 years and older with acute coronary syndrome. J Clin Lipidol. (2021) 15:466–76. doi: 10.1016/j.jacl.2021.04.003
9. Tsimikas S. Elevated lipoprotein(a) and the risk of stroke in young, adults, and the elderly. Eur Heart J. (2021) 42:2197–200. doi: 10.1093/eurheartj/ehab251
10. Mazidi M, Rezae P, Karimi E, Kengne AP. The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. (2017) 227:850–7. doi: 10.1016/j.ijcard.2016.10.011
11. Aujuotil I, Jacquemin P, Rietzschel E, Scheen A, Tréfois P, Wens J, et al. Factors associated with clinical inertia: an integrative review. Adv Med Educ Pract. (2014) 5:141–47. doi: 10.2147/AMEP.S59022
12. Lloyd-Sherlock P, McKee M, Ebrahim S, Gorman M, Greengross S, Prince M, et al. Population ageing and health. Lancet. (2012) 379:1295–96. doi: 10.1016/S0140-6736(12)60519-4
13. Ahadi S, Zhou W, Schüssler-Fiorenza Rose SM, Sailani MR, Contrepois K, Avina M, et al. Personal aging markers and ageotypes revealed by deep longitudinal profiling. Nat Med. (2020) 26:83–90. doi: 10.1038/s41591-019-0179-5
14. Khan SU, Khan MZ, Raghu Subramanian C, Riaz H, Khan MU, Lone AN, et al. Participation of women and older participants in randomized clinical trials of lipid-lowering therapies: a systematic review. JAMA Netw Open. (2020) 3:e205202. doi: 10.1001/jamanetworkopen.2020.5202
15. Cholesterol Treatment Trialsists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. (2010) 376:1670–81. doi: 10.1016/S0140-6736(10)61350-5

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.699477/full#supplementary-material

16. Ruscia M, Macchi C, Pavanello C, Corsini A, Sahébkar A, Sirtori CR. Appropriateness of statin prescription in the elderly. Eur J Intern Med. (2018) 50:33–40. doi: 10.1016/j.ejim.2017.12.011
17. Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. (2020) 396:1637–43. doi: 10.1016/S0140-6736(20)32332-1
18. Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. (2019) 290:140–205. doi: 10.1016/j.atherosclerosis.2019.08.014
19. Newman BP, Preiss D, Tobjart JA, Jacobson TA, Page RL, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. (2019) 39:e38–81. doi: 10.1161/ATV.0000000000000881
20. Piccinni C, Antonazzo IC, Maggiorno AP, Pedrini A, Calabria S, Ronconi G, et al. PCSK9 inhibitors’ new users: analysis of prescription patterns and patients’ characteristics from an Italian real-world study. Clin Drug Investig. (2020) 40:173–81. doi: 10.1007/s40261-019-00877-3
21. Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur Heart J. (2020) 41:2248–58. doi: 10.1093/eurheartj/ehz809
22. Navar AM, Mulder HM, Wojdyla DM, Peterson ED. Have the major cardiovascular outcomes trials impacted payer approval rates for PCSK9 inhibitors? Circ Cardiovasc Qual Outcomes. (2020) 13:e006019. doi: 10.1161/CIRCOUTCOMES.119.006019
23. Elsawy B, Higgins KE. The geriatric assessment. Am Fam Physician. (2011) 83:48–56.
24. Ruscia M, Ferri N, Santos RD, Sirtori CR, Corsini A. Lipid lowering drugs: present status and future developments. Curr Atheroscler Rep. (2021) 23:17. doi: 10.1007/s11883-021-00918-3

Conflict of Interest: SDP reports grants and personal fees from AstraZeneca, Boheringer Ingelheim, Novartis; and personal fees from Applied Therapeutics, Eli Lilly, GlaxoSmithKline, Novo Nordisk, Laboratoires Servier, Sanofi, and Takeda Pharmaceuticals. GD has received research funding from Eli Lilly and AstraZeneca. GP reports lecture fees from AstraZeneca, Roehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Sigma-Tau, and Takeda, and travel grants from AstraZeneca, Novo Nordisk, and Takeda.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Dardano, Daniele, Penno, Miccoli and Del Prato. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.